Cancer Care, Reimagined
Cancer treatment is often costly and complex. Coordinating multiple specialists, managing diverse treatment modalities, and delivering medication regimens in the most cost-effective and convenient ways can place significant strain on health plans and create challenges for both members and healthcare providers.
Traditionally, hospital-based models for delivering infusions have been the standard approach. However, these methods are not always ideal as they tend to be:
- Inconvenient and impersonal
- Associated with a higher risk of infection due to exposure to respiratory illnesses and hospital-acquired infections
- Less preferred by patients, as research indicates that 73% of cancer patients would rather receive treatments at home than in a clinical setting1
A Smarter, Safer Site of Care for Immunotherapy
CareCentrix’s approach shifts the delivery of immunotherapy infusions from the high-cost hospital setting to more efficient, member-friendly environments, such as home-based or Ambulatory Infusion Center/Ambulatory Infusion Suite (AIC/AIS) care. Our model seamlessly integrates with a health plan’s existing oncology program, ensuring high-quality, compassionate care that achieves equal or better overall outcomes than traditional hospital-based treatments—all at a lower cost.
In addition to cost savings, health plans can realize the following benefits for their members:
- Enhanced experience, convenience and quality of life
- Improved health through stronger adherence to treatment plans
- Reduced exposure to infections
- Optimized safety through program eligibility and monitoring protocols
The CareCentrix Value
Beyond access to our network of high-quality home infusion providers, our Oncology at Home solution offers:
Utilization Management
Ensures members receive appropriate services and the correct level of care in accordance with the health plan’s guidelines and recommended timeframes. This includes authorizing the site of care — including home, AIC, or AIS – to support safe and effective treatment.
Member and Physician Outreach
Close collaboration with members and prescribing physicians to ensure all parties are aligned and confident in the decision to transition care.
Safe and Seamless Care Transition
Coordination of transition of immunotherapy infusion services, following the first 2-3 doses administered in the facility as an extra safety measure.
Continuous Monitoring and Reporting
Adverse event reporting, infusion reaction monitoring and medication reconciliation.
Active Drug Pipeline Monitoring
Real-time monitoring of FDA pipeline and approvals to enable growth of list of eligible home-administered immunotherapies.